安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评价

Evaluation of the efficacy and safety of amlotinib in the treatment of advanced non-small cell lung cancer

目的:探讨安罗替尼治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:回顾性分析应用安罗替尼治疗的50例晚期NSCLC病人资料,其中有45例病人接受安罗替尼三线治疗,5例病人接受四线治疗。分析评估安罗替尼的疗效及安全性。结果:最终47例病人纳入研究,无完全缓解的病人,部分缓解2例(4.26%),病情稳定24例(51.06%),病情进展21例(44.68%)。客观缓解率及疾病控制率分别是4.26%和55.32%,中位总生存时间(mOS)及中位无进展生存时间(mPFS)分别是8.6个月(95%CI 5.853~11.347)和4.8个月(95%CI 2.904~6.696);≥60岁病人mOS及mPFS分别为8.6个月(95%CI 5.853~11.347)、5.8个月(95%CI 4.283~7.317)。使用安罗替尼发生的不良反应基本可耐受,发生率较高的不良反应为厌食、咯血、肝功能异常、手足综合征、高血压。结论:安罗替尼作为晚期NSCLC病人三线及以上治疗是可行的方案。

Objective:To explore the efficacy and safety of anlotinib in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:The clinical data of 50 advanced NSCLC patients treated with anlotinib were retrospectively analyzed.Forty-five patients were treated with anrotinib of third-line drug,and 5 patients were treated with fourth-line drug.The efficacy and safety of anlotinib were analyzed.Results:Forty-seven patients were investigated,and the complete response in 0 case,partial response in 2 cases(4.26%),stable disease in 24 cases(51.06%)and disease progression in 21 cases(44.68%)were found.The objective response rate(ORR)and disease control rate(DCR)were 4.3%and 55.3%,respectively.The median overall survival(mOS)and median progression-free survival(mPFS)were 8.6 months(95%CI 5.853-11.347)and 4.8 months(95%CI 2.904-6.696),respectively.The mOS and mPFS in elderly patients(≥60 years old)were 8.6 months(95%CI 5.853-11.347)and 5.8 months(95%CI 4.283-7.317),respectively.The adverse reactions caused by the use of amlotinib were basically tolerable,and the high incidence rate of adverse reactions included anorexia,hemoptysis,abnormal liver function,hand-foot syndrome and hypertension.Conclusions:Anlotinib is a viable option for third-line and above in patients with advanced NSCLC.